Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

Clinics offering ketamine infusions and injections for “treatment-resistant depression” are today claiming 24-48 hours ...

The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures ...

Shares of Neumora Therapeutics, Inc. (NMRA) are down more than 80% at $1.81 in premarket trading Thursday, following the release of ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...

Neumora Therapeutics Inc. (NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing ...

PTSD is a serious mental health condition marked by changes in mood, intrusive memories, avoidant behavior, and a heightened ...

The changing landscape of health care during COVID-19 placed focus on increasing accessibility to mental health resources other than the emergency department (ED), with potential savings of over $ ...

Neumora Therapeutics to release phase 3 data on Navacaprant for MDD treatment in 2024. Check out NMRA's catalysts that might ...

The following is a summary of “Service coverage for major depressive disorder: estimated rates of minimally adequate ...